# Evaluate the Efficacy and Safety of ACTIQ in Patients With Cancer and Breakthrough Pain

> **NCT00236145** · PHASE3 · COMPLETED · sponsor: **Cephalon**

## Conditions studied

- Breakthrough Pain

## Interventions

- **DRUG:** ACTIQ (Oral transmucosal fentanyl citrate)

## Key facts

- **NCT ID:** NCT00236145
- **Lead sponsor:** Cephalon
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-06
- **Primary completion:** 2005-08
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2013-01-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00236145

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00236145, "Evaluate the Efficacy and Safety of ACTIQ in Patients With Cancer and Breakthrough Pain". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT00236145. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*